Company Description
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine.
In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab.
It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2008 |
| IPO Date | Oct 8, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 120 |
| CEO | Dr. Sean A. McCarthy DPHIL |
Contact Details
Address: 151 Oyster Point Blvd., Suite 400 South San Francisco, California 94080 United States | |
| Phone | 650.515.3185 |
| Website | cytomx.com |
Stock Details
| Ticker Symbol | CTMX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001501989 |
| CUSIP Number | 23284F105 |
| ISIN Number | US23284F1057 |
| Employer ID | 27-3521219 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sean A. McCarthy DPHIL | Chairman and Chief Executive Officer |
| Dr. Marcia P. Belvin Ph.D. | Senior Vice President and Chief Scientific Officer |
| Jeffrey Landau B.S., M.B.A. | Senior Vice President, Head of Strategy and Chief Business Officer |
| Christopher W. Ogden | Senior Vice President of Finance and Accounting |
| Lloyd A. Rowland Jr., J.D. | Senior Vice President, General Counsel, Chief Compliance Officer and Secretary |
| Danielle Olander-Moghadassian | Senior Vice President and Chief Human Resources Officer |
| Leslie Robbins | Senior Vice President of Intellectual Property |
| Dr. Yu-Waye Chu M.D. | Senior Vice President and Chief Medical Officer |
| Dawn Benson | Senior Vice President of Quality and Product Manufacturing |
| Dr. Hoyoung Huh M.D., Ph.D. | Special Advisor to Chief Executive Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 11, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 11, 2024 | 8-K | Current Report |
| Mar 11, 2024 | 10-K | Annual Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |